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A substantial proportion of randomized clinical trials (RCTs) initially presented in conference proceedings are not published as full articles afterward. 1, 2 For example, a survey of 510 large phase 3 RCTs presented at American Society of Clinical Oncology (ASCO) annual meetings over 10 years found that 26% of them were not published. 1 Thus, a meeting abstract may provide the only permanent information about an RCT that had been executed. The 2008 Consolidated Standards of Reporting Trials (CONSORT) for Abstracts defined a minimum list of essential items to include when reporting RCTs in abstracts. 3 Herein, we assess the quality of ASCO abstracts of RCTs based on the CONSORT guidelines.
Methods | We identified primary reports of comparative RCTs in the 2007 and 2015 ASCO proceedings. The data abstraction form was modified from the CONSORT checklist and consist of 21 items (Table) . 4 Two trained assessors (X.L. and Y.-P.C.) carried out single data extraction with uncertainties resolved by consensus. The concordance was good (Cohen's κ, 0.6-1.0) in 15 randomly selected abstracts assessed by both reviewers. The number of items scored as "yes" was compared using a nonparametric test. Statistical analyses were performed using STATA statistical software (version 12; STATA Corp). A 2-sided α of less than 0.05 was considered significant. The median number of items scored as "yes" increased from 9 in 2007 to 11 in 2015 (Table) . We observed an increase in the proportion of reports that provided primary outcome (87.1% vs 67.4%; difference, 19.6%; 95% CI, 11.5%-27.8%; P < .001), number of participants randomized to each group (46.0% vs 34.3%; difference, 11.7%; 95% CI, 2.2%-21.3%; P = .018), precision of effect size (40.6% vs 21.7%; difference, 20.4%; 95% CI, 11.7%-29.1%; P < .001), and registry information (93.3% vs 1.7%; difference, 91.6%; 95% CI, 87.8%-95.4%; P < .001), and scored "yes" for blinding (16.1% vs 5.6%; difference, 10.5%; 95% CI, 4.6%-16.3%; P < .001).
In 2015, only 1 (0.4%) abstract described the methods of allocation concealment. Most abstracts (156 [69.6%]) didn't report the status of blinding. No abstract detailed specifically who was blinded. Sixty-one (27.2%) abstracts reported the number of participants analyzed in each group. Only 136 abstracts (60.7%) provided the effect size, and 91 (40.6%) provided precision. The reporting of phase 3 RCTs was comparable with the results in all trials.
Discussion | Poorly-reported RCTs were associated with exaggerated estimates of intervention efficacy.
5 Word limitations are a frequently cited reason why essential information may be missing from abstracts. However, this is unlikely to be a main barrier for better reporting of RCTs in ASCO abstracts, which have higher word limitations (300 to 350) than that recommended by the CONSORT (250 to 300). 3 Large conferences receive considerable numbers of abstracts. For example, the ASCO 2015 received 5945 abstracts. Reviewing so many abstracts is time-consuming and stressful, and the reviewers' evaluation of abstracts may not be as reproducible as expected. 6 If authors were to follow a comprehensive guide like the CONSORT for abstracts, the heterogeneity in reporting may be minimized, which would facilitate the review process and improve the quality of abstracts, as observed in journal abstracts. 4 Although encouraging improvement in the reporting of RCTs in ASCO abstracts has occurred in recent years, the overall reporting quality remains below an acceptable level. an attempt to extend a previously reported pooled analysis by Cortazar et al. 2 Cortazar et al 2 estimated an individual-level association between pathologic complete response (pCR) and event-free survival (EFS), and a trial-level association between the effects of anti-human epidermal growth factor receptor 2 (HER2) therapies on pCR and EFS. Their results clearly demonstrated that there is a strong individual-level association between pCR and EFS, but virtually no association between treatment effects on these end points, which implies that no reliable prediction can be made about the effect that a new treatment will have on EFS, based on the effect of this treatment on pCR. These results applied to breast cancer in general, but doubts remained in HER2-positive disease, of which there were only few trials. Adding a larger number of studies in HER2-positive disease, many of which are retrospective or single-arm/cohort studies, Broglio et al 1 now argue that such a prediction is possible. Toward this end, they propose to derive trial-level associations from a model that relies on the survival experience that would be expected by groups of patients with different pCR rates. This approach has no mathematical justification, as explained elsewhere. 3, 4 Moreover, inspection of their Figure 3B and D allows the conclusion that the predictions (represented by the straight lines) do not fit the data (represented by the circles). Hence, one can question the validity of the model underlying the predictions. Finally, the authors argue that their predictions are in broad agreement with the observed outcomes of the ALTTO and NeoSPHERE trials, but the prediction intervals are so wide that almost any reasonable prediction would have called for a similar conclusion, something that makes their results uninformative. For all these reasons, before a conclusion is drawn one way or another, we need more convincing statistical evidence that improvements in pCR indeed reliably predict improvements in EFS. Randomized trials with long-term follow-up will eventually provide enough data to confirm the hypothesis of Broglio et al. 1 For the benefit of patients and of clinical development of promising new drugs, we sincerely hope that their hypothesis is correct. Trial-level analyses correlate the benefit of a therapy for pCR rate with its benefit for event-free survival (EFS). The experimental unit is the trial. Patient-level analyses compare EFS for patients who experience pCR and those who do not. The experimental unit is the patient.
The US Food and Drug Administration (FDA)-led metaanalysis in the study by Cortazar et al 1 addresses both analyses. The authors clearly explain why they found high predictability of pCR in patient-level analyses but no correlation in trial-level analysis, repeating some of these explanations in the FDA's guidance for using pCR as an end point to support accelerated approval. 2 Their Figure 6 plots hazard ratio for EFS against odds ratio for pCR for 10 trials. 1 So the power of having more than 10 000 patients is reduced to 10 data points. And because most of the trials showed no treatment effect, it would be almost impossible to show a correlation. The 10 points are essentially noise. Figure 6 provides a nice example that it is difficult to correlate something with a treatment effect that does not exist. Burzykowski et al claim that there is "no mathematical justification" for using patient-level results to predict long-term trial results. The justification is simple arithmetic. Take a patient-level conclusion as a hypothesis. Consider any one of the panels in Figure 5 by Cortazar et al, 1 showing EFS for those patients experiencing pCR vs not. Assume that these curves apply for both therapies in a clinical trial-I address this hypothesis herein. If control therapy shows a 30% pCR rate, then, under the hypothesis, 30% of the patients will be on the EFS curve for pCR and 70% will be on the EFS curve for no pCR. Take the weighted average of the 2 curves. Do the same for experimental therapy with its assumed pCR rate. Compare the 2 weighted averages. Simple. As the examples and plots in our article show, the hazard ratio of EFS for the 2 treatments will be much less impressive than when comparing EFS curves for 100% and 0% pCRs. Obviously, this hypothesis may be wrong. A therapy that has particular effects on the tumor in the breast and lymph nodes
